Price (90d)
No price history yet — the daily price refresh runs once a day.
Signal Score (90d)
80Quote
Valuation & Ratios
Returns & Efficiency
Revenue & Net Income (Annual)
| Fiscal Year | Revenue | Net Income | EPS |
|---|---|---|---|
| 2026 | $353.47B | $45.09B | $53.92 |
| 2025 | $325.54B | $56.54B | $67.85 |
| 2024 | $279.16B | $55.68B | $66.80 |
| 2023 | $245.88B | $45.07B | $54.29 |
| 2022 | $214.39B | $23.57B | $28.42 |
Social Signal Score
Earnings
Fri, Oct 23(in 2 months)
Consensus estimate $0.10 per share
Typical surprise -4.1% (median, so one quarter with a near-zero estimate can't distort it)
- Tue, Jul 21$0.06 vs $0.09miss
- Mon, May 11$0.06 vs $0.09miss
- Tue, Jan 20$0.16 vs $0.16beat
- Fri, Oct 24$0.19 vs $0.19miss
- Wed, Jul 23$0.20 vs $0.21miss
- Fri, May 9$0.22 vs $0.21beat
Estimates and results for RDY via Financial Modeling Prep. Beating consensus says the company cleared the bar analysts set, not that the business grew.
Valuation
Project earnings forward and see what return today's price implies.
Seeded from RDY's reported EPS growth of 17.4% a year over 4 years.
- EPS in 5 years
- $120.80
- Implied price
- $2,899
- Return from $12.27
- 198.3% a year
To earn 15.0% a year on these assumptions you'd need to buy at $1,441 — today's price is already 99.1% below that.
How sensitive is that answer?
Annual return across nearby assumptions. If the result is only attractive in one corner, that is the finding.
| growth \ P/E | 16 | 20 | 24 | 28 | 32 |
|---|---|---|---|---|---|
| 7.4% | 151.7% | 163.1% | 172.9% | 181.5% | 189.1% |
| 12.4% | 163.4% | 175.4% | 185.6% | 194.6% | 202.5% |
| 17.4% | 175.1% | 187.6% | 198.3% | 207.7% | 216.0% |
| 22.4% | 186.8% | 199.9% | 211.0% | 220.8% | 229.4% |
| 27.4% | 198.5% | 212.1% | 223.7% | 233.9% | 242.9% |
This is arithmetic on assumptions you chose, not a forecast or a recommendation. It ignores dividends, buybacks, share issuance and debt, and it assumes a company still earning money in 5 years. Change any input and the answer changes a lot — that sensitivity is the honest result, not a flaw in the model.
Mentions (1)
- Newsbusinesswire.com·1d ago·Negative
RDY SHAREHOLDER ALERT: Dr. Reddy's Laboratories Investors Encouraged to Contact Kirby McInerney LLP About Potential Securities Laws Violations NEW YORK--(BUSINESS WIRE)---- $RDY #classactionlawsuit--The law firm of Kirby McInerney LLP reminds investors of its investigation on behalf of Dr. Reddy's Laboratories (“Dr. Reddy's” or the “Company”) (NYSE: RDY) investors concerning the Company's and/or members of its senior management's possible violation of the federal securities laws or other unlawfu…
View source ↗